Raju Prasad - 14 Mar 2023 Form 4 Insider Report for CRISPR Therapeutics AG (CRSP)

Role
Chief Financial Officer
Signature
/s/ Elizabeth Ryland Waldinger, attorney-in-fact
Issuer symbol
CRSP
Transactions as of
14 Mar 2023
Net transactions value
$0
Form type
4
Filing time
14 Mar 2023, 17:50:19 UTC
Next filing
17 Oct 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRSP Restricted Stock Units Award $0 +40,000 $0.000000 40,000 14 Mar 2023 Common Shares 40,000 Direct F1, F2
transaction CRSP Stock Option (Right to Buy) Award $0 +100,000 $0.000000 100,000 14 Mar 2023 Common Shares 100,000 $45.15 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F2 This restricted stock unit award was granted on March 14, 2023 with respect to 40,000 Common Shares, with (i) one quarter of the shares vesting on March 14, 2024, (ii) one quarter of the shares vesting on March 14, 2025, (iii) one quarter of the shares vesting on March 14, 2026, and (iv) one quarter of the shares vesting on March 14, 2027.
F3 This option was granted on March 14, 2023 with respect to 100,000 Common Shares, with 25% of the shares vesting on March 14, 2024 and the remaining shares vesting on each monthly anniversary thereafter for a period of 36 months.